$吉利德科学(GILD)$ 吉利德CEO在公司官网上的最新声明：初步临床数据在接下来的几周会出来，如果获批，会保证药物供给并且保证病人负担得起，目前有超过1000病人在使用瑞德西韦Multiple studies are ongoing, and we are on track to have initial data in the coming weeks. If it is approved, we will work to ensure affordability and access so that remdesivir is available to patients with the greatest need.

In the meantime, we have made the investigational medicine available for severely ill patients who cannot enroll in a trial. This “compassionate use” program is typically reserved for a small number of individual cases but there is nothing typical about this crisis and to date we have provided remdesivir to more than 1,000 patients. 原文链接：网页链接